<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10507770</article-id><article-id pub-id-type="pmc">2362927</article-id><article-id pub-id-type="pii">6690715</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690715</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Couteau</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chouaki</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Leyvraz</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Oulid-Aissa</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lebecq</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Domenge</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Groult</surname><given-names>V</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bordessoule</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Janot</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Forni</surname><given-names>M De</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Armand</surname><given-names>J-P</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Institut Gustave Roussy, Department of Medecine, 39 rue Camille Desmoulins, Villejuif, 94805, France</aff><aff id="aff2"><label>2</label>Rhone Poulenc Rorer, Antony, France</aff><aff id="aff3"><label>3</label>Centre Pluridisciplinaire d'Oncologie, University Hospital, Lausanne, Switzerland</aff><pub-date pub-type="ppub"><month>10</month><year>1999</year></pub-date><volume>81</volume><issue>3</issue><fpage>457</fpage><lpage>462</lpage><history><date date-type="received"><day>20</day><month>04</month><year>1998</year></date><date date-type="rev-recd"><day>26</day><month>03</month><year>1999</year></date><date date-type="accepted"><day>20</day><month>04</month><year>1999</year></date></history><copyright-statement>Copyright 1999, Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>This study was designed to evaluate the activity, safety and tolerance of docetaxel (D) in a selected population with metastatic squamous cell carcinoma of the head and neck (SCCHN). Twenty-four patients with no prior palliative therapy were enrolled and received D 100 mg m<sup>&#x02212;2</sup> by 1 h of infusion, every 3 weeks. All but two patients had been evaluated for efficacy on lung metastatic sites. No prophylactic administration of anti-emetics or growth factors was given. A pharmacokinetic study was performed in 22 patients. Twenty-one patients were assessable for response and 24 for toxicity. One hundred and four cycles were administered with a median of 4.5 (range 1&#x02013;9) per patient. The median cumulative dose was 449 mg m<sup>&#x02212;2</sup>. Partial responses were achieved in five patients with a median duration of 18.7 weeks (range 13.1&#x02013;50.3). The overall response rate was 20.8&#x00025; with a median duration of 11.0 weeks (range 2.4&#x02013;52.6). The most frequent side-effect was neutropenia (79.2&#x00025; grade IV) but with a short duration (median 4 days) and no febrile neutropenia. The incidence of moderate/severe fluid retention was 29.2&#x00025; with one treatment discontinuation. Other toxicities (all grades) were common (skin 75&#x00025;, asthenia 50&#x00025;, infection 29.2&#x00025;, nausea 16.7&#x00025;, diarrhoea 12.5&#x00025;, stomatitis 16.7&#x00025;, vomiting 8.3&#x00025; and HSR 8.3&#x00025;). A mean clearance of 19.6 l h<sup>&#x02212;1</sup> m<sup>&#x02212;2</sup> and an area under the curve of 6.00 &#x003bc;g ml<sup>&#x02212;1</sup> h<sup>&#x02212;1</sup> was found in the pharmacokinetic analysis. Docetaxel is active in this selected population with metastatic SCCHN, with a good tolerance. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>docetaxel</kwd><kwd>head and neck carcinoma</kwd><kwd>phase II trial</kwd></kwd-group></article-meta></front></article>


